My lede:

A Food and Drug Administration task force in May unveiled a series of 21 proposals to share publicly more information about pending or rejected drug and device applications, as well as agency enforcement actions. The move, which has drawn objections from companies fearful that greater disclosure will spill trade secrets, is part of a larger transparency drive the FDA launched last year.

The whole shebang.